Phase 2 trial of "sandwich" @entity4445 , @entity1891 , and @entity229 chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/ XXXX .

@entity1 @entity137 @entity706 @entity229 @entity784 @entity4445 @entity1891 @entity1431
BACKGROUND: Extranodal natural killer/ @entity784 (ENKTL), nasal-type, is a distinct entity of lymphoid tissue. ENKTL is sensitive to radiotherapy (RT), but the prognosis is poorer than for other types of @entity706 . The treatment schedule is controversial. METHODS: A phase 2 study was conducted of "sandwich" protocols, with earlier RT after an initial 2 to 3 cycles of LVP ( @entity4445 , @entity1891 , and @entity229 ), followed by further "consolidation" cycles. @entity1 aged 18 years and older who had previously untreated ENKTL and localized lesions in the upper aerodigestive tract were enrolled. The primary endpoints were objective response rate and complete remission rate. The secondary endpoints were 2-year overall survival, 2-year progression-free survival, and @entity137 . This study is registered with www.Chictr.org, number ChicTR-TNC-00000394, and is ongoing for long-term follow-up. RESULTS: Twenty-six @entity1 completed total therapy, which resulted in 88.5% response that included 21 @entity1 (80.8%) with complete response (CR) and 2 @entity1 (7.7%) with partial response. Three (11.5%) of 26 @entity1 progressed during therapy. With a median follow-up of 27 months (range, 4-35 months), the 2-year overall survival was 88.5%, and the 2-year progression-free survival was 80.6%. @entity1 with CR had better prognosis than @entity1 without CR. Only 2 @entity1 (7.7%) experienced grade 3 @entity1431 . No grade 4 @entity137 or treatment-related deaths were observed. CONCLUSIONS: The research showed that the "sandwich" protocol of LVP combined with RT was a safe and effective treatment for localized nasal natural killer/ @entity784 , and the results warrant further investigation into this protocol.
